alexa Advances in NKT cell Immunotherapy for Glioblastoma | OMICS International| Abstract
ISSN: 1948-5956

Journal of Cancer Science & Therapy
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Review Article   
  • J Cancer Sci Ther/Vol.10.6 145(2018),
  • DOI: 10.4172/1948-5956.1000533

Advances in NKT cell Immunotherapy for Glioblastoma

Kalyani Pyaram1* and Viveka Nand Yadav2*
1Department of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, USA
2Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, USA
*Corresponding Author (s) : Kalyani Pyaram, Department of Microbiology and Immunology, University of Michigan Medical School, 5737 Medical Science Building II, Ann Arbor, USA, Tel: +1734-936-4000, Email: [email protected]
Viveka Nand Yadav, Department of Neurosurgery, University of Michigan Medical School, 4576 Medical Science Research Building II, Ann Arbor, USA, Tel: +1734- 936-4000, Email: [email protected]

Received Date: May 11, 2018 / Accepted Date: Jun 15, 2018 / Published Date: Jun 18, 2018

Abstract

Type I or invariant natural killer T cells belong to a unique lineage of innate T cells, which express markers of both T lymphocytes and NK cells, namely T cell receptor (TCR) and NK1.1 (CD161C), respectively. Thus, apart from direct killing of target cells like NK cells, and they also produce a myriad of cytokines which modulate the adaptive immune responses. Unlike traditional T cells which carry a conventional ab TCR, NKT cells express semiinvariant TCR – Va14-Ja18, coupled with Vb8, Vb7 and Vb2 in mice. In humans, the invariant TCR is composed of Va24-Ja18, coupled with Vb11.

Keywords: NKT cell immunotherapy; Glioblastoma; T-cell receptor; T-lymphocyte; Cancer immunity; Brain tumor cells; Solid tumors

Citation: Pyaram K, Yadav V (2018) Advances in NKT cell Immunotherapy for Glioblastoma. J Cancer Sci Ther 10: 145-148. Doi: 10.4172/1948-5956.1000533

Copyright: © 2018 Pyaram K, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Select your language of interest to view the total content in your interested language

Post Your Comment Citation
Share This Article
Relevant Topics
Recommended Conferences
Article Usage
  • Total views: 2180
  • [From(publication date): 0-2018 - Dec 09, 2019]
  • Breakdown by view type
  • HTML page views: 2100
  • PDF downloads: 80
Top